TITLE

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

AUTHOR(S)
HOLLANDER, PRISCILLA; GUPTA, ALOK K.; PLODKOWSKI, RAYMOND; GREENWAY, FRANK; BAYS, HAROLD; BURNS, COLLEEN; KLASSEN, PRESTON; FUJIOKA, KEN
PUB. DATE
December 2013
SOURCE
Diabetes Care;Dec2013, Vol. 36 Issue 12, p4022
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/ 360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS--This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of $5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss $10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids. RESULTS--In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m², and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (25.0 vs. 21.8%; P< 0.001) and proportion of patients achieving $5% weight loss (44.5 vs. 18.9%, P< 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (20.6 vs. 20.1% [6.6 vs. 1.1 mmol/mol]; P< 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P< 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS--NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
ACCESSION #
92533597

 

Related Articles

  • Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin. FERRANNINI, ELE; BERK, ANDREAS; HANTEL, STEFAN; PINNETTI, SABINE; HACH, THOMAS; WOERLE, HANS J.; BROEDL, ULI C. // Diabetes Care;Dec2013, Vol. 36 Issue 12, p4015 

    OBJECTIVE--To investigate the long-term safety and efficacy of empagliflozin, a sodium glucose cotransporter 2 inhibitor; sitagliptin; and metformin in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS--In this randomized, open-label, 78-week extension study of two 12-week, blinded,...

  • Adipose Dipeptidyl Peptidase-4 and Obesity. SELL, HENRIKE; BLUHER, MATTHIAS; KLÖTING, NORA; SCHLICH, RAPHAELA; WILLEMS, MIRIAM; RUPPE, FLORIAN; KNOEFEL, WOLFRAM TRUDO; DIETRICH, ARNE; FIELDING, BARBARA A.; ARNER, PETER; FRAYN, KEITH N.; ECKEL, JURGEN // Diabetes Care;Dec2013, Vol. 36 Issue 12, p4083 

    OBJECTIVE--To study expression of the recently identified adipokine dipeptidyl peptidase-4 (DPP4) in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) of patients with various BMIs and insulin sensitivities, as well as to assess circulating DPP4 in relation to obesity and...

  • Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. YKI-JÄRVINEN, HANNELE; ROSENSTOCK, JULIO; DURÁN-GARCIA, SANTIAGO; PINNETTI, SABINE; BHATTACHARYA, SUDIPTA; THIEMANN, SANDRA; PATEL, SANJAY; WOERLE, HANS-JUERGEN // Diabetes Care;Dec2013, Vol. 36 Issue 12, p3875 

    OBJECTIVE--To evaluate the efficacy and long-term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents. RESEARCH DESIGN AND METHODS--A total of 1,261 patients (HbA1c ≥7.0% [53 mmol/mol] to ≤10.0%[86...

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial. El ghormli, Laure // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1742 

    OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on...

  • Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes. Weinzimer, Stuart A.; Sherr, Jennifer L.; Cengiz, Eda; Kim, Grace; Ruiz, Jessica L.; Carria, Lori; Voskanyan, Gayane; Roy, Anirban; Tamborlane, William V. // Diabetes Care;Oct2012, Vol. 35 Issue 10, p1994 

    OBJECTIVE--Even under closed-loop (CL) conditions, meal-related blood glucose (BG) excursions frequently exceed target levels as a result of delays in absorption of insulin from the subcutaneous site of infusion. We hypothesized that delaying gastric emptying with preprandial injections of...

  • Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Leung, Lawrence; Birtwhistle, Richard; Kotecha, Jyoti; Hannah, Susan; Cuthbertson, Sharon // British Journal of Nutrition;2009, Vol. 102 Issue 12, p1703 

    It has been estimated that up to one-third of patients with diabetes mellitus use some form of complementary and alternative medicine. Momordica charantia (bitter melon) is a popular fruit used for the treatment of diabetes and related conditions amongst the indigenous populations of Asia, South...

  • Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). NATHAN, DAVID M.; BUSE, JOHN B.; KAHN, STEVEN E.; KRAUSE-STEINRAUF, HEIDI; LARKIN, MARY E.; STATEN, MYRLENE; WEXLER, DEBORAH; LACHIN, JOHN M. // Diabetes Care;Aug2013, Vol. 36 Issue 8, p2254 

    OBJECTIVE--The epidemic of type 2 diabetes (T2DM) threatens to become the major public health problem of this century. However, a comprehensive comparison of the long-term effects of medications to treat T2DM has not been conducted. GRADE, a pragmatic, unmasked clinical trial, aims to compare...

  • Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Häring, Hans-Ulrich; Merker, Ludwig; Seewaldt-Becker, Elke; Weimer, Marc; Meinicke, Thomas; Broedl, Uli C.; Woerle, Hans J. // Diabetes Care;Jun2014, Vol. 37 Issue 6, p1650 

    OBJECTIVE To investigate the efficacy and tolerability of empagliflozin as an add-on to metformin therapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Patients with HbA1c levels of ≥7% to ≤ 10% (≥53 to ≤86 mmol/mol) while receiving metformin (≥1,500...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics